FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2039407184> ?p ?o ?g. }

• W2039407184 endingPage "113" @default.
• W2039407184 startingPage "103" @default.
• W2039407184 abstract "BackgroundBecause chemotherapy for metastatic breast cancer (MBC) is associated with relevant toxicity, sequential monotherapy trastuzumab followed by cytotoxic therapy at disease progression might be an attractive approach.MethodsIn a multicenter phase II trial, 101 patients with overexpression of human epidermal growth factor receptor 2 (HER2+) MBC were randomized between combination-therapy trastuzumab (Herceptin) plus docetaxel (H+D) and sequential therapy of single-agent trastuzumab followed at disease progression by docetaxel alone (H→D) as first-line chemotherapy for metastatic disease. The primary endpoint was progression-free survival (PFS) after completed sequential or combination therapy.ResultsFor the H+D group the median PFS was 9.4 vs. 9.9 months for the H→D group and 1-year PFS rates were 44% vs. 35%, respectively. However the overall response rates (ORRs) were 79% vs. 53%, respectively (P = .016), and overall survival was 30.5 vs. 19.7 months, respectively (P = .11). In the H→D group, response rates to monotherapy trastuzumab and subsequent docetaxel were 34% and 39%, respectively, with a median PFS during single-agent trastuzumab of 3.9 months. The incidence and severity of neuropathy were significantly higher in the H+D group. Retrospective analysis of trastuzumab treatment beyond progression (applied in 46% of patients in the H+D group and 37% in the H→D group) showed a correlation with longer overall survival in both treatment arms (36.0 vs. 18.0 months and 30.3 vs. 18.6 months, respectively).ConclusionFirst-line treatment in patients with MBC with H→D resulted in a similar PFS compared with H+D, but the response rate was lower and the overall survival nonsignificantly shorter." @default.
• W2039407184 created "2016-06-24" @default.
• W2039407184 creator A5018004001 @default.
• W2039407184 creator A5019431922 @default.
• W2039407184 creator A5022233428 @default.
• W2039407184 creator A5028311501 @default.
• W2039407184 creator A5028380474 @default.
• W2039407184 creator A5030619231 @default.
• W2039407184 creator A5031023319 @default.
• W2039407184 creator A5047950538 @default.
• W2039407184 creator A5049517577 @default.
• W2039407184 creator A5050032230 @default.
• W2039407184 creator A5072417115 @default.
• W2039407184 creator A5076494423 @default.
• W2039407184 creator A5078372826 @default.
• W2039407184 creator A5082638530 @default.
• W2039407184 creator A5083080568 @default.
• W2039407184 creator A5084179743 @default.
• W2039407184 creator A5086248761 @default.
• W2039407184 date "2011-04-01" @default.
• W2039407184 modified "2023-10-18" @default.
• W2039407184 title "Randomized Phase II Study Comparing Efficacy and Safety of Combination-Therapy Trastuzumab and Docetaxel vs. Sequential Therapy of Trastuzumab Followed by Docetaxel Alone at Progression As First-Line Chemotherapy in Patients with HER2+ Metastatic Breast Cancer: HERTAX Trial" @default.
• W2039407184 cites W1914269090 @default.
• W2039407184 cites W1988737162 @default.
• W2039407184 cites W1989456077 @default.
• W2039407184 cites W2014296185 @default.
• W2039407184 cites W2034414538 @default.
• W2039407184 cites W2035076441 @default.
• W2039407184 cites W2040689610 @default.
• W2039407184 cites W2100375606 @default.
• W2039407184 cites W2103019840 @default.
• W2039407184 cites W2104337757 @default.
• W2039407184 cites W2109369818 @default.
• W2039407184 cites W2115759102 @default.
• W2039407184 cites W2118191456 @default.
• W2039407184 cites W2130900820 @default.
• W2039407184 cites W2137086207 @default.
• W2039407184 cites W2139248078 @default.
• W2039407184 cites W2140055441 @default.
• W2039407184 cites W2149773268 @default.
• W2039407184 cites W2149997750 @default.
• W2039407184 cites W2156677665 @default.
• W2039407184 cites W2157684259 @default.
• W2039407184 cites W2158158704 @default.
• W2039407184 cites W2167766783 @default.
• W2039407184 cites W2318605753 @default.
• W2039407184 doi "https://doi.org/10.1016/j.clbc.2011.03.003" @default.
• W2039407184 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21569996" @default.
• W2039407184 hasPublicationYear "2011" @default.
• W2039407184 type Work @default.
• W2039407184 sameAs 2039407184 @default.
• W2039407184 citedByCount "57" @default.
• W2039407184 countsByYear W20394071842012 @default.
• W2039407184 countsByYear W20394071842013 @default.
• W2039407184 countsByYear W20394071842014 @default.
• W2039407184 countsByYear W20394071842015 @default.
• W2039407184 countsByYear W20394071842016 @default.
• W2039407184 countsByYear W20394071842017 @default.
• W2039407184 countsByYear W20394071842018 @default.
• W2039407184 countsByYear W20394071842019 @default.
• W2039407184 countsByYear W20394071842020 @default.
• W2039407184 countsByYear W20394071842021 @default.
• W2039407184 countsByYear W20394071842022 @default.
• W2039407184 countsByYear W20394071842023 @default.
• W2039407184 crossrefType "journal-article" @default.
• W2039407184 hasAuthorship W2039407184A5018004001 @default.
• W2039407184 hasAuthorship W2039407184A5019431922 @default.
• W2039407184 hasAuthorship W2039407184A5022233428 @default.
• W2039407184 hasAuthorship W2039407184A5028311501 @default.
• W2039407184 hasAuthorship W2039407184A5028380474 @default.
• W2039407184 hasAuthorship W2039407184A5030619231 @default.
• W2039407184 hasAuthorship W2039407184A5031023319 @default.
• W2039407184 hasAuthorship W2039407184A5047950538 @default.
• W2039407184 hasAuthorship W2039407184A5049517577 @default.
• W2039407184 hasAuthorship W2039407184A5050032230 @default.
• W2039407184 hasAuthorship W2039407184A5072417115 @default.
• W2039407184 hasAuthorship W2039407184A5076494423 @default.
• W2039407184 hasAuthorship W2039407184A5078372826 @default.
• W2039407184 hasAuthorship W2039407184A5082638530 @default.
• W2039407184 hasAuthorship W2039407184A5083080568 @default.
• W2039407184 hasAuthorship W2039407184A5084179743 @default.
• W2039407184 hasAuthorship W2039407184A5086248761 @default.
• W2039407184 hasBestOaLocation W20394071841 @default.
• W2039407184 hasConcept C121608353 @default.
• W2039407184 hasConcept C126322002 @default.
• W2039407184 hasConcept C143998085 @default.
• W2039407184 hasConcept C168563851 @default.
• W2039407184 hasConcept C203092338 @default.
• W2039407184 hasConcept C2775930923 @default.
• W2039407184 hasConcept C2776694085 @default.
• W2039407184 hasConcept C2776999253 @default.
• W2039407184 hasConcept C2779786085 @default.
• W2039407184 hasConcept C2780739268 @default.
• W2039407184 hasConcept C2781190966 @default.
• W2039407184 hasConcept C530470458 @default.
• W2039407184 hasConcept C71924100 @default.
• W2039407184 hasConcept C90924648 @default.
• W2039407184 hasConceptScore W2039407184C121608353 @default.

• next